Cargando…
Treatment of Advanced Metastatic Melanoma
The introduction in clinical practice of new drug compounds both targeted therapies anti-BRAF and checkpoint inhibitors have largely improved our potential to manage advanced metastatic melanoma patients. This has led to a significant improvement in terms of response rates and particularly in the ov...
Autores principales: | Quaglino, Pietro, Fava, Paolo, Tonella, Luca, Rubatto, Marco, Ribero, Simone, Fierro, Maria Teresa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mattioli 1885
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366308/ https://www.ncbi.nlm.nih.gov/pubmed/34447613 http://dx.doi.org/10.5826/dpc.11S1a164S |
Ejemplares similares
-
Anti-BRAF/anti-MEK targeted therapies for metastatic melanoma patients during the COVID-19 outbreak: experience from an Italian skin cancer unit
por: Quaglino, Pietro, et al.
Publicado: (2021) -
Clinical Significance of Distant Metastasis-Free Survival (DMFS) in Melanoma: A Narrative Review from Adjuvant Clinical Trials
por: Amabile, Simone, et al.
Publicado: (2021) -
Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer
por: Rubatto, Marco, et al.
Publicado: (2023) -
Cutaneous side effects and types of dermatological reactions in metastatic melanoma patients treated by immunotherapies or targeted therapies: A retrospective single center study
por: Gullo, Giulia, et al.
Publicado: (2022) -
Prognostic and Predictive Biomarkers in Stage III Melanoma: Current Insights and Clinical Implications
por: Tonella, Luca, et al.
Publicado: (2021)